Skip to content

Ipratropium

Atrovent, Atrovent Hfa (ipratropium) is a small molecule pharmaceutical. Ipratropium was first approved as Atrovent on 1986-12-29. It is used to treat allergic rhinitis perennial, bronchial spasm, bronchitis, pulmonary emphysema, and vasomotor rhinitis in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M4. Ipratropium bromide's patent is valid until 2030-01-17 (FDA).
Trade Name Atrovent, Atrovent Hfa
Common Name Ipratropium
Indication allergic rhinitis perennial, bronchial spasm, bronchitis, pulmonary emphysema, vasomotor rhinitis
Drug Class Quaternary ammonium derivatives; atropine derivatives
Ipratropium
Get full access now